𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia

✍ Scribed by J. L. Jurlina; A. R. Varcoe; J. W. Paxton

Publisher
Springer
Year
1985
Tongue
English
Weight
503 KB
Volume
14
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Serum levels of angiogenin, basic fibrob
Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia
✍ Nils Glenjen; Knut Anders Mosevoll; Øystein Bruserud πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 204 KB

Angiogenesis seems to be important both in the pathogenesis of acute myelogenous leukemia (AML) and for the susceptibility of AML blasts to chemotherapy. Recent clinical studies even suggest that antiangiogenic therapy can induce disease control in patients with AML relapse. In this context we have

Demonstration of antibody-associated cel
Demonstration of antibody-associated cellular cytotoxicity in patients with acute myelogenous leukemia before and after chemotherapy
✍ R. FΓ€ldt; J. Ankerst πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 French βš– 814 KB

## Abstract This study demonstrates that a cytotoxic serum reactivity not requiring the presence of complement appears in the sera of patients with acute myelogenous leukemia. The reaction is detected upon short‐term incubation of sera in vitro with autochthonous mononuclear white blood cells from